Olanzapine: Review of safety 2008

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 761-769

  Kantrowitz, Joshua T ^a   Citrome, Leslie ^b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic side effects; Antipsychotic induced weight gain; Effectiveness; Olanzapine

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CLOZAPINE; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; AMINOTRANSFERASE BLOOD LEVEL; ANTICHOLINERGIC SYNDROME; AREA UNDER THE CURVE; BEDTIME DOSAGE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR MANIA; BRADYCARDIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DEMENTIA; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENSTRUATION DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PLASMA HALF LIFE; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; URINARY HESITANCY; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; PROLACTIN; RISK FACTORS; WEIGHT GAIN;

EID: 57049123316     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802423234     Document Type: Review

References (97)

1. Zyprexa. Anon. 2008. Available from: http://pi.lilly.com/us/ zyprexa-pi.pdf [Last accessed 2008 May 21]
2. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1(2):133-52
3. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
4. Stahl SM. Stahl's Essential Psychopharmacology. 3rd edition. Cambridge, UK: Cambridge University Press; 2008
5. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(5):368-78
6. Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):1021-8
7. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008;48(2):157-65
8. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-9
9. Briefing Document for Olanzapine Pamoate (OP) Depot.United States Food and Drug Administration Pharmacological Drugs Advisory Committee. 2008 February 6. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/08/ briefing/2008-4338bl-03-Lilly.pdf [Last accessed 2008 June 8]
10. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
11. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
13. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97
14. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch of Gen Psychiatry 2006;63(10):1079-87
15. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-85
16. Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005;13(1):28-42
17. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-9
18. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57(9):841-9
19. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263-71
20. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88
21. Brown EB, McElroy SL, Keck PEJ, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxerine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2003;67(7):1025-33
22. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
23. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63(12):1148-55
24. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159(6):1011-7
25. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60(12):1218-26
26. Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006;67(11):1747-53
27. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162(10):1879-87
28. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189(2):259-66
29. Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006;86(1-3):234-43
30. Kinon BJ, Noordsy DL, Liu-Seifert H, et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006;26(5):453-61
31. Lieberman JA, McEvoy JP, Perkins DO, et al. Comparison of atypicals in first-episode psychosis: A randomized, 52-week comparison of olanzapine, quetiapine, and risperidone [abstract no. P.3.163]. Eur Neuropsychopharmacol 2005;15(3 Suppl):S526
32. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(18 Suppl):47-56
33. Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007;22(3):145-52
34. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693-702
35. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
36. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18
37. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43
38. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162(7):1281-90
39. Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26(2):157-62
40. Dossenbach M, Pachecho Z, Toledo D, et al. Patterns of antipsychotic-induced weight change: 3-year results from the intercontinental schizophrenia outpatient-health outcomes (IC-SOHO) study [abstract no. P.3.c.021]. Eur Neuropsychopharmacol 2006;16(4 Suppl):S407-8
41. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17(4):235-44
42. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62(2):92-100
43. Kinon BJ, Volavka J, Stauffer VL, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed dose study. J Clin Psychopharmacol 2008;28(4):392-400
44. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006;26(3):316-20
45. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008;102(1-3):230-40
46. Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120(2):18-33
47. Mokdad AH, Ford ES, Bowman BA, et al. The continuing increase of diabetes in the US. Diabetes Care 2001;24(2):412
48. Citrome L, Jaffe A, Levine J, et al. Incidence, prevalence, and surveillance for diabetes in New York State Psychiatric Hospitals, 1997-2004. Psychiatr Serv 2006;57(8):1132-9
49. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70(1):19-26
50. Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36(1):62-7
51. Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 1996;53(1):25-31
52. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29(3):697-701
53. Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005;19(6 Suppl):47-55
54. Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007;68(11):1682-90
55. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160(2):290-6
56. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161(10):1837-47
57. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162(8):1535-8
58. Smith RC, lindenmayer A, Buga A, et al. Metabolic changes during 5 months treatment with olanzapine or risperidone: preliminary results from randomized trial [abstract]. Schizophr Bull 2005;31(2):570
59. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186(4):572-8
60. Beasley CMJ, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23(6):582-94
61. Chrome L, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41(10):1593-603
62. Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006;26(5):504-7
63. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14(1):59-64
64. Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005;19(6 Suppl):102-9
65. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64(5):598-4
66. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158(5):765-74
67. Citrome L. Olanzapine: interpreting the label change. Int J Clin Pract 2007;61(12):1960-2
68. Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int J Clin Pract 2008;62(5):837-40
69. Yang S-Y, Kao Yang Y-H, Chong M-Y, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based Study. Clin Pharmacol Ther 2007;81(4):586-94
70. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9
71. Correll, CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151-6
72. Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005;66(9):1130-3
73. Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005;53(8):1374-9
74. Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care 2007;13(Suppl):1-12
75. Svestka J, Synek O, Tomanová J, et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007; 28(6):881-8
76. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Clin Psychopharmacol 2008;22(2 Suppl):46-55
77. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65(1):57-61
78. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2007;22(2 Suppl):90-7
79. Schiavi RC, Stimmel BB, Mandeli J, et al. Diabetes, psychological function and male sexuality. J Psychosom Res 1995;39(3):305-14
80. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55(9):406-13
81. Javaid MK, Holt RIG. Understanding osteoporosis. J Psychopharmacol 2008;22(2 Suppl):38-45
82. Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22(2 Suppl):98-103
83. Goder R, Fritzer G, Gottwald B, et al. Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia. Pharmacopsychiatry 2008;41(3):92-9
84. Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008;69(2):302-9
85. Citrome L. Atypical antipsychotics, elderly patients, and moraity risk. South Med J 2007;100(1):964-5
86. Beasley CMJ, Tollefson GD, Tran PV. Safety of Olanzapine. J Clin Psychiatry 1997;58(10 Suppl):13-7
87. Hedges D, Jeppson K, Whitehead P. Antipsychocic medication and seizures: a review. Drugs Today 2003;39(7):551-7
88. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome - a case review. Hum Psychopharmacol 2003;18(4):301-9
89. Norgard NB, Stark JE. Olanzapine-Associated Neuroleptic Malignant Syndrome. Pharmacotherapy 2006;26(8):1180-2
90. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164(6):870-6
91. Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003;28(4):253-61
92. Citrome L, Kantrowitz J. Using antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008;8(7):1079-91
93. Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60(8):933-40
94. Martinez-Arán A, Vieta E, Chengappa KN, et al. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disord 2008;10(5):566-79
95. Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23(10):2551-7
96. Berenson A. Eli Lilly Said to Play Down Risk of Top Pill. New York Times. December 17, 2006. Available from: http://www.nytimes.com/2006/12/ 17/business/17drug.html [Last accessed 2008 Sept 3]
97. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13(9):1102-7